The clinicopathological and prognostic significances of CDC73 expression in breast cancer: A pathological and bioinformatics analysis

Parafibromin is a protein encoded by the oncosuppressor CDC73 gene, whose mutation results in fibromin is linked to lung, gastric, colorectal, and was detected by RT-PCR, bioinformatics analysis, Western blot, and immunohistochemistry; and compared with clinicopathological characteristics of breast cancer. CDC73-related genes and pathways were analyzed using increased in breast cancer compared to normal tissues at both mRNA and protein levels (p<0.05). Among triplenegative breast cancers, it was higher in basal-like 1 than basal-like 2 patients (p<0.05) and mesenchymal than expression was positively correlated with white race, subtypes of PAM50, and prognosis of breast cancer patients (p<0.05). The differential genes of CDC73 were classified into enzyme inhibitors, peptidase, and (p<0.05) and mucinous adenocarcinoma than others (p<0.05). Parafibromin immunoreactivity as an independent factor was positively associated with an increased overall survival rate of breast cancer patients (p<0.05). These findings suggest that up-regulation of parafibromin in breast cancer patients is closely linked to a favorable prognosis. It is involved in tumorigenesis and subsequent progression by regulating metabolism, ribosomes, and cytokines.